Randomized Comparisons of Bevacizumab(B) and Irinotecan(I), Added to Temozolomide(T), In Children With Relapsed/Refractory High-Risk Neuroblastoma(RR-HRNB); Survival Results of the ITCC-SIOPEN Beacon-Neuroblastoma Phase 2 Trial

被引：0

作者：

Wheatley, K. ^{[1
]}

Holt, G. ^{[1
]}

Owens, C. ^{[2
]}

Valteau-Couanet, D. ^{[3
]}

Gambart, M. ^{[4
]}

Castel, V. ^{[5
]}

Van Eijkelenburg, N. ^{[6
]}

Castellano, A. ^{[7
]}

Nysom, K. ^{[8
]}

Gerber, N. ^{[9
]}

Laureys, G. ^{[10
]}

Ladenstein, R. ^{[11
,12
]}

Makin, G. ^{[13
]}

Vaidya, S. ^{[14
]}

Thebaud, E. ^{[15
]}

Kearns, P.

Pearson, A. ^{[1
,16
]}

Moreno, L. ^{[17
]}

机构：

[1] Univ Birmingham, Canc Res Uk Clin Trials Unit, Birmingham, W Midlands, England

[2] Our Ladys Childrens Hosp, Pediat Haemat Oncol, Dublin, Ireland

[3] Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Villejuif, France

[4] Hop Enfants, Unite Hematooncol, Toulouse, France

[5] Hosp Univ & Politecn La Fe, Paediat Oncol & Haematol, Valencia, Spain

[6] Princess Maxima Ctr Pediat Oncol, Pediat Oncol, Utrecht, Netherlands

[7] Bambino Gesu Pediat Hosp, Paediat Oncol Unit, Rome, Italy

[8] Rigshosp, Paediat & Adolescent Med, Copenhagen, Denmark

[9] Univ Childrens Hosp Zurich, Dept Pediat Oncol, Zurich, Switzerland

[10] Ghent Univ Hosp, Paediat Oncol & Haematol, Ghent, Belgium

[11] Med Univ, Dept Paediat, St Anna Childrens Hosp, Vienna, Austria

[12] Med Univ, Dept Paediat, Childrens Canc Res Inst CCRI, Vienna, Austria

[13] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[14] Royal Marsden Hosp, Children & Young Peoples Unit, London, England

[15] CHU Nantes, Pediat Oncol, Nantes, France

[16] Institute Canc Res Retired, Pediat, London, England

[17] Hosp Univ Vall dHebron, Pediat Oncohematol Serv, Barcelona, Spain

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0055

引用

页码：S31 / S31

页数：1

共 10 条

[1] Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.
Wheatley, Keith
Holt, Grace
Owens, Cormac
Laidler, Jennifer
Valteau-Couanet, Dominique
Gambart, Marion
Castel, Victoria
van Eijkelenburg, Natasha
Castellano, Aurora
Nysom, Karsten
Gerber, Nicolas U.
Laureys, Genevieve
Ladenstein, Ruth Lydia
Makin, Guy
Vaidya, Sucheta
Thebaud, Estelle
Kearns, Pamela
Pearson, Andrew D. J.
Moreno, Lucas
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial
Moreno, L.
Moroz, V.
Owens, C.
Valteau-Couanet, D.
Gambart, M.
Castel, V.
van Eijkelenburg, N.
Castellano, A.
Nysom, K.
Gerber, N.
Laureys, G.
Ladenstein, R.
Thebaud, E.
Murphy, D.
Morland, B.
Vaidya, S.
Elliott, M.
Pearson, A. D.
Wheatley, K.
ANNALS OF ONCOLOGY, 2019, 30 : 901 - 901
[3] Temozolomide versus Irinotecan-Temozolomide for Children with Relapsed and or Refractory High-Risk Neuroblastoma (RR-HRNB). Results of the Beacon-Neuroblastoma Randomized Phase II Trial, an ITCC-SIOPEN Trial
Moreno, L.
Moroz, V.
Owens, C.
Valteau-Couanet, D.
Gambart, M.
van Eijkelenburg, N.
Zwaan, C. M.
Castel, V.
Murphy, D.
Morland, B.
Gray, J.
Marshall, L.
Burchill, S.
Chesler, L.
Peet, A.
Schleiermacher, G.
Fenwick, N.
Kearns, P.
Pearson, A.
Wheatley, K.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S34 - S34
[4] Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Moreno, Lucas
Weston, Rebekah
Owens, Cormac
Valteau-Couanet, Dominique
Gambart, Marion
Castel, Victoria
Zwaan, C. Michel
Nysom, Karsten
Gerber, Nicolas
Castellano, Aurora
Laureys, Genevieve
Ladenstein, Ruth
Roessler, Jochen
Makin, Guy
Murphy, Dermot
Morland, Bruce
Vaidya, Sucheta
Thebaud, Estelle
van Eijkelenburg, Natasha
Tweddle, Deborah A.
Barone, Giuseppe
Tandonnet, Julie
Corradini, Nadege
Chastagner, Pascal
Paillard, Catherine
Bautista, Francisco J.
Gallego Melcon, Soledad
De Wilde, Bram
Marshall, Lynley
Gray, Juliet
Burchill, Susan A.
Schleiermacher, Gudrun
Chesler, Louis
Peet, Andrew
Leach, Martin O.
Mchugh, Kieran
Hayes, Roisin
Jerome, Neil
Caron, Hubert
Laidler, Jennifer
Fenwick, Nicola
Holt, Grace
Moroz, Veronica
Kearns, Pamela
Gates, Simon
Pearson, Andrew D. J.
Wheatley, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (10) : 1135 - 1145
[5] Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACONNeuroblastoma randomized phase 2 trial A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.
Moreno, Lucas
Moroz, Veronica
Owens, Cormac
Laidler, Jennifer
Valteau-Couanet, Dominique
Gambart, Marion
Castel, Victoria
Van Eijkelenburg, Natasha
Castellano, Aurora
Nysom, Karsten
Gerber, Nicolas U.
Laureys, Genevieve
Ladenstein, Ruth Lydia
Makin, Guy
Vaidya, Sucheta
Thebaud, Estelle
Kearns, Pamela
Pearson, Andrew D. J.
Wheatley, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] RESULTS OF THE DINUTUXIMAB BETA, BEVACIZUMAB, IRINOTECAN AND TOPOTECAN RANDOMISATIONS OF THE BEACON-NEUROBLASTOMA PHASE 2 TRIAL BY ITCC AND SIOPEN
Moreno, Lucas
Weston, Rebekah
Owens, Cormac
Gray, Juliet
Barone, Giuseppe
Valteau-Couanet, Dominique
Simon, Alba Rubio San
Makin, Guy
Vaidya, Sucheta
Gambart, Marion
Castel, Victoria
Van Eijkelenburg, Natasha
Nysom, Karsten
Laureys, Genevieve
Ladenstein, Ruth
Castellano, Aurora
Gerber, Nicolas
Laidler, Jennifer
Kearns, Pamela
Wheatley, Keith
PEDIATRIC BLOOD & CANCER, 2022, 69
[7] A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.
Moreno, Lucas
Laidler, Jennifer
Moroz, Veronica
Owens, Cormac
Rubie, Herve
Berlanga, Pablo
Castellano, Aurora
Nysom, Karsten
Ladenstein, Ruth L.
Rossler, Jochen
Zwaan, Christian M.
Elliott, Martin
Makin, Guy
Murphy, Dermot
Burchill, Susan A.
Jerome, Neil
Rousseau, Raphael F.
Kearns, Pamela
Wheatley, Keith
Pearson, Andrew D. J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study
Wagner, Lars M.
Villablanca, Judith G.
Stewart, Clinton F.
Crews, Kristine R.
Groshen, Susan
Reynolds, C. Patrick
Park, Julie R.
Maris, John M.
Hawkins, Randall A.
Daldrup-Link, Heike E.
Jackson, Hollie A.
Matthay, Katherine K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1290 - 1296
[9] Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (sclL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
Lode, Holger N.
Valteau-Couanet, Dominique
Gray, Juliet
Luksch, Roberto
Wieczorek, Aleksandra
Castel, Victoria
Ash, Shifra
Laureys, Genevieve
Papadakis, Vassilios
Owens, Cormac
Garaventa, Alberto
Manzitti, Carla
Siebert, Nikolai
Troschke-Meurer, Sascha
Glogova, Evgenia
Poetschger, Ulrike
Ladenstein, Ruth Lydia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Academic, Phase I/II Trial on T Cells Expressing a Third-Generation GD2 Chimeric Antigen Receptor and Inducible Caspase-9 Safety Switch for Treatment of Relapsed/Refractory High-Risk Neuroblastoma
Del Bufalo, F.
Del Baldo, G.
Mastronuzzi, A.
Serra, A.
De Ioris, M. A.
Castellano, A.
Caruana, I.
Bertaina, V.
Sinibaldi, M.
Di Cecca, S.
DeAngelis, B.
Garganese, M. C.
Merli, P.
Pira, G. Li
Pagliara, D.
Leone, G.
Quintarelli, C.
Locatelli, F.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S53 - S54

← 1 →